GE Healthcare and M+W Group aim to capture a share of the rapidly expanding global biologics market with a new plant and manufacturing tech partnership.
Large volume production is a must for the cell therapy sector according to ATMI, which claims the latest addition to its single-use bioreactor range can help manufacturers overcome the GMP hurdles that hinder commercial scale-up.
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
Multinational biotech giant, Lonza, has completed the acquisition of US-based Arch Chemicals as the company bids to tap into the microbial control sector.
CellCura has inked an agreement with IDT Biologika for the testing and adaptation of its protein-free (PF) media for the production of cell lines for vaccine manufacturing.
DSM Biologicals has launched a new production method designed to streamline downstream processing during biopharmaceutical manufacturing that, it claims, makes making mAB-based drugs more cost effective.
Catalent Pharma Solutions and German expression system developer Cevec Pharmaceuticals have partnered to create a cell development service that, they claim, will help drugmakers generate stable lines faster.
Sartorius Stedim Biotech (SSB) has teamed up with packaging firm Sudpack Medica AG in a deal focused on making plastic films for biopharmaceutical industry applications.
Florida-based contract manufacturing organisation (CMO), Goodwin Biotechnology (GBI), has entered into an agreement with protein and monoclonal antibody drug developer, Rafagen, to provide cell line engineering and biological contract manufacturing services.
Biologics Process Development, a wholly-owned subsidiary of Californian contract research organisation (CRO), Viropro, has announced it is to double the size of its bioprocess and scale-up laboratory.
Californian Bioreactor manufacturer, PBS Biotech, has launched its new PBS 3 single-use bioreactor system for the development of biological therapeutics, vaccines and biosimilars.
Sartorius Stedim Biotech (SSB) has launched a new small-scale bioreactor citing growing biopharmaceutical company demand for scale-up technologies as the key driver for its development.
Almac Pharma Services has expanded its cold storage capacity for biopharmaceuticals, continuing the contract manufacturing organisation’s (CMO) busy expansion programme.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences.
Crucell and Eden Biodesign have entered into an agreement that sees Eden become a provider of services of contract manufacturing services for Crucell's PER.C6 cell-line technology.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
Covance has added a 40,000 sq ft biotech laboratory to its site in Indiana, US site to support its relationship with Eli Lilly and boost capacity outside Europe.
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
ATMI is using Interphex 2010 to launch the Integrity PadReactor, a disposable bioreactor designed to provide a highly scalable entry point in its line of mixing and process manufacturing systems.
PPD has added capabilities at the facility acquired from Merck & Co and improved integration of other sites to create its Vaccines & Biologics Center of Excellence, a single provider of multiple laboratory services.
Industrial filtration specialist Pall and testing firm Sotax say their new co-marketing deal is only first stage of planned pharmaceutical industry certification solutions partnership.
Pall says its acquisition of MicroReactor Technologies (MRT) broadens its offering in the $1bn (€689m) a year global biopharmaceutical process development market.
A recently completed manufacturing and filling capacity expansion will help Florida Biologix meet deadlines and win repeat business according to company director Richard Snyder.
Laureate Pharma and Selexis SA have entered into a joint-marketing relationship, drawing on their respective strengths in contract manufacturing and cell line development to shorten timelines.
The Nucleotide Research Complex, the largest such facility in the Middle East, is now operational and ready to house companies’ research and development, analytical, diagnostic and equipment training activities.
Continued high demand for vaccine manufacturing technologies saw life sciences emerge as one of the few positives for industrial processing specialist Pall in Q1.
SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.
US contract research organisation (CRO) PPD has set its sights on the Asian biopharma sector with new a lab at the heart of Singapore’s rapidly expanding drug development and trial industry.
Angel Biotechnology has inked a deal to manufacture the CTX stem cell line, which can now be frozen and thawed when needed, at its dedicated cell-based therapies plant that is equipped and licensed for the task.